Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. Scribe – which counts new Nobel Prize for chemistry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results